Oncobiologics is a privately held biopharmaceutical company that has rapidly progressed from early seed funding to recognition of significant commercial revenue.  Funding sources have included:

  1. U.S. Government Grant:   The U.S. government recognized the promise of Oncobiologics in 2011 with a significant grant from the Qualifying Therapeutic Discovery Project Program(QTDP). QTDP was designed to fund start-up companies that focus on reducing healthcare costs in the U.S., curing cancer and job creation.
  2. Series A: Angel investors provided significant seed capital to support company launch and early operations.
  3. Series B:A global corporate investor provided Series B funding, which sustained operations until achievement of revenue.

In addition, Oncobiologics qualified for and received government backed financing for equipment and facilities through the Small Business Administration (SBA).

Within 18 months of the official commissioning of the Oncobiologics R&D facility, the company achieved important revenue milestones through regional licensing partnerships and is now largely self-sustaining through revenue.  Oncobiologics believes the pace at which we achieved revenue reflects the flexibility of our business model, the high quality of our biosimilar assets and the dedication of our team.


For additional information, please contact